Stroke is typically seen as the biggest danger for patients after they receive an AFib diagnosis. This study, however, suggests heart failure could be an even bigger threat.

The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials. This can impact the device's performance, creating a heightened risk of injury or death. 

Gregg Stone, MD, explains the details of the late-breaking RELIEVE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.

CMS has issued its proposed rule for the 2025 Medicare hospital inpatient prospective payment system, suggesting a payment increase of 2.6%. According to the American Hospital Association, this update would not be enough at a time when hospitals are already struggling to stay open. 

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

Eko Health worked closely with Mayo Clinic to develop and evaluate its latest AI offering. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations," one clinician said. 

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.